PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000974380.14929.94 |
| _version_ | 1797279867003207680 |
|---|---|
| author | Anand Patel Laura Michaelis Gary Schiller Ronan Swords Lawrence E. Morris Luis A. Carvajal Gordon Bray Elizabeth A. Olek Richard Cutler Jorge Dimartino Eytan Stein |
| author_facet | Anand Patel Laura Michaelis Gary Schiller Ronan Swords Lawrence E. Morris Luis A. Carvajal Gordon Bray Elizabeth A. Olek Richard Cutler Jorge Dimartino Eytan Stein |
| author_sort | Anand Patel |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:32:12Z |
| format | Article |
| id | doaj.art-0fcdebe12f7f4ca5b2f0a3bf48e1eb43 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:32:12Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-0fcdebe12f7f4ca5b2f0a3bf48e1eb432024-03-03T10:07:38ZengWileyHemaSphere2572-92412023-08-017e149299410.1097/01.HS9.0000974380.14929.94202308003-01769PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AMLAnand Patel0Laura Michaelis1Gary Schiller2Ronan Swords3Lawrence E. Morris4Luis A. Carvajal5Gordon Bray6Elizabeth A. Olek7Richard Cutler8Jorge Dimartino9Eytan Stein101 The University of Chicago Medical Center, Chicago, United States2 Medical College of Wisconsin, Milwaukee, United States3 University of California Los Angeles (UCLA), Los Angeles, United States4 Oregon Health and Science University, Portland, United States5 Blood Marrow Transplant Group Of Georgia, Atlanta, United States6 Kronos Bio, San Mateo, United States6 Kronos Bio, San Mateo, United States6 Kronos Bio, San Mateo, United States6 Kronos Bio, San Mateo, United States6 Kronos Bio, San Mateo, United States7 Memorial Sloan Kettering Cancer Center New York, New York, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000974380.14929.94 |
| spellingShingle | Anand Patel Laura Michaelis Gary Schiller Ronan Swords Lawrence E. Morris Luis A. Carvajal Gordon Bray Elizabeth A. Olek Richard Cutler Jorge Dimartino Eytan Stein PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML HemaSphere |
| title | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_full | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_fullStr | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_full_unstemmed | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_short | PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML |
| title_sort | pb1889 kb lanra 1001 a phase 1b 2 study on safety pk pd and preliminary efficacy of the selective syk inhibitor lanraplenib in combination with the flt3 inhibitor gilteritinib in flt3 mutated r r aml |
| url | http://journals.lww.com/10.1097/01.HS9.0000974380.14929.94 |
| work_keys_str_mv | AT anandpatel pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT lauramichaelis pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT garyschiller pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT ronanswords pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT lawrenceemorris pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT luisacarvajal pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT gordonbray pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT elizabethaolek pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT richardcutler pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT jorgedimartino pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml AT eytanstein pb1889kblanra1001aphase1b2studyonsafetypkpdandpreliminaryefficacyoftheselectivesykinhibitorlanraplenibincombinationwiththeflt3inhibitorgilteritinibinflt3mutatedrraml |